PRA Health Sciences Inc (NASDAQ:PRAH) has earned an average recommendation of “Buy” from the thirteen analysts that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $114.25.
A number of brokerages have commented on PRAH. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Friday, March 22nd. Mizuho set a $100.00 price objective on PRA Health Sciences and gave the stock a “hold” rating in a research report on Friday, May 3rd. SunTrust Banks raised their price objective on PRA Health Sciences to $120.00 and gave the stock an “average” rating in a research report on Monday, March 4th. ValuEngine lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Finally, Wolfe Research began coverage on PRA Health Sciences in a research report on Tuesday, April 2nd. They set a “market perform” rating for the company.
Several institutional investors have recently made changes to their positions in the company. Motco lifted its holdings in PRA Health Sciences by 937.0% in the 1st quarter. Motco now owns 280 shares of the medical research company’s stock worth $31,000 after purchasing an additional 253 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new stake in PRA Health Sciences in the 1st quarter worth approximately $53,000. Manchester Capital Management LLC acquired a new stake in PRA Health Sciences in the 1st quarter worth approximately $57,000. CENTRAL TRUST Co lifted its holdings in PRA Health Sciences by 28.2% in the 1st quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock worth $93,000 after purchasing an additional 185 shares during the last quarter. Finally, Enlightenment Research LLC acquired a new stake in PRA Health Sciences in the 4th quarter worth approximately $101,000. Institutional investors and hedge funds own 99.42% of the company’s stock.
PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.10 EPS for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.15. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. The firm had revenue of $722.00 million during the quarter, compared to analyst estimates of $730.84 million. During the same period last year, the company posted $0.85 EPS. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. As a group, sell-side analysts expect that PRA Health Sciences will post 4.63 earnings per share for the current fiscal year.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: Put Option
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.